Merck drug shows promise in bladder cancer

September 29, 2014 1:50 PM

16 0

KEYTRUDA is suggested for use in the U.S. at a dose of 2 mg/kg every three weeks to help treat patients with unrespectable or metastatic melanoma and disease progression.

Merck announced the initial presentation of data on the investigational use of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in PD-L1 positive, advanced urothelial cancer, otherwise known as bladder cancer. Results from the early findings indicated a confirmed overall 24 percent response rat...

Also read: Chipmaker SK Hynix reports 64 percent jump in 1Q earnings

Read more

To category page